ChronoScale Corporation Common Stock (NASDAQ:CHRN) and Elekta (OTCMKTS:EKTAY) Head-To-Head Analysis

ChronoScale Corporation Common Stock (NASDAQ:CHRN) and Elekta (OTCMKTS:EKTAY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.

Volatility and Risk

ChronoScale Corporation Common Stock has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500. Comparatively, Elekta has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.

Valuation and Earnings

This table compares ChronoScale Corporation Common Stock and Elekta”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ChronoScale Corporation Common Stock	$12.80 million	5.11	-$11.69 million	($5.38)	-3.41
Elekta	$1.78 billion	1.15	-$55.30 million	($0.16)	-34.75

ChronoScale Corporation Common Stock has higher earnings, but lower revenue than Elekta. Elekta is trading at a lower price-to-earnings ratio than ChronoScale Corporation Common Stock, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

6.4% of ChronoScale Corporation Common Stock shares are held by institutional investors. 6.9% of ChronoScale Corporation Common Stock shares are held by company insiders. Comparatively, 41.3% of Elekta shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares ChronoScale Corporation Common Stock and Elekta’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ChronoScale Corporation Common Stock	-135.66%	-197.81%	-74.17%
Elekta	-3.32%	10.67%	3.21%

Analyst Ratings

This is a breakdown of current recommendations and price targets for ChronoScale Corporation Common Stock and Elekta, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ChronoScale Corporation Common Stock	1	1	0	0	1.50
Elekta	2	0	0	0	1.00

ChronoScale Corporation Common Stock currently has a consensus price target of $6.00, indicating a potential downside of 67.32%. Given ChronoScale Corporation Common Stock’s stronger consensus rating and higher possible upside, analysts clearly believe ChronoScale Corporation Common Stock is more favorable than Elekta.

Summary

ChronoScale Corporation Common Stock beats Elekta on 7 of the 13 factors compared between the two stocks.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.

About Elekta

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.